Pinsky PF, et al. - Researchers sought for the burden of total metastatic disease in all men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Men with metastases at diagnosis were compared with men with metastatic progression in terms of survival. In PLCO, the intervention arm comprised 38,340 men and the control arm included 38,343 men. The two arms had 4,974 and 4,699 prostate cancer cases, respectively. The arms showed comparable rates of total metastatic disease and metastatic progression in PLCO. Men with metastatic progression had worse survival vs those with metastatic disease at diagnosis.